Children with atopic dermatitis may be smaller and heavier than healthy children Presented ByProf. Amy Paller, Northwestern University‘s Feinberg School of Medicine, USA TrialPEDISTAD ConferenceAAD 2024 22 April, 2024 16:54
Amlitelimab leads to a high response 28 weeks after treatment discontinuation Presented ByProf. Stephan Weidinger, Christian-Albrechts-University Kiel, Germany TrialPhase 2, STREAM-AD ConferenceAAD 2024 22 April, 2024 15:35
Delgocitinib cream: A promising treatment option for chronic hand eczema Presented ByProf. Melinda Gooderham, Queens University, Canada TrialPhase 3, DELTA 3 ConferenceAAD 2024 22 April, 2024 15:31
Tapinarof on course to become a new topical treatment in AD Presented ByDr Jonathan Silverberg, George Washington University, USA TrialPhase 3, ADORING ConferenceEADV 2023 28 November, 2023 13:43
Upadacitinib provides sustained skin clearance in adolescents and adults with AD Presented ByDr Jonathan Silverberg, George Washington University, USA TrialPhase 3, Measure Up; AD UP ConferenceEADV 2023 28 November, 2023 13:39
Sustained deep clinical and itch responses with novel IL-13 inhibitor Presented ByProf. Eric Simpson, Oregon Health & Science University, USA TrialPhase 3, ADvocate; ADvantage ConferenceEADV 2023 28 November, 2023 13:13
IL-13 inhibitor shows potential in atopic dermatitis Presented ByProf. Eric Simpson, Oregon Health and Science University, USA TrialPhase 2, TREK-AD ConferenceEADV 2023 28 November, 2023 13:08
Encouraging results for amlitelimab in atopic dermatitis Presented ByProf. Stephan Weidinger, University Hospital Schleswig-Holstein, Germany TrialPhase 2, STREAM-AD ConferenceEADV 2023 28 November, 2023 13:03
Frequent co-existence of atrial fibrillation and obstructive sleep apnoea in stroke patients Presented ByDr Maria Rita Lo Monaco, Catholic University of the Sacred Heart, Italy ConferenceHFA 2023 8 August, 2023 16:27
As-needed ruxolitinib shows successful long-term symptom control in AD Presented ByDr Andrew Blauvelt, Oregon Medical Research Center, OR, USA TrialPhase 3, TRuE-AD1 and TRuE-AD2 ConferenceAAD 2023 15 May, 2023 11:43
Dupilumab: a viable option for atopic hand and foot eczema Presented ByProf. Eric Simpson, Oregon Health & Science University, OR, USA TrialPhase 3, LIBERTY-AD-HAFT ConferenceAAD 2023 15 May, 2023 11:33
Topical roflumilast beneficial in atopic dermatitis Presented ByProf. Lawrence Eichenfield, University of California San Diego, CA, USA TrialPhase 3, INTEGUMENT-1 and INTEGUMENT-2 ConferenceAAD 2023 15 May, 2023 11:27
IL-22 receptor blocker reduces itch and skin lesions in AD Presented ByProf. Diamant Thaçi, University of Lübeck, Germany TrialPhase 2 ConferenceAAD 2023 15 May, 2023 11:17
Delgocitinib shows promise as topical therapy for chronic hand eczema Presented ByDr Robert Bissonnette, Innovaderm Research, Canada TrialPhase 3, DELTA 1 ConferenceAAD 2023 15 May, 2023 10:58
Eligibility and selection of JAK inhibitors for constitutional eczema Presented ByDr Dirk Jan Hijnen, Erasmus MC, the Netherlands ConferenceDDD 2023 10 May, 2023 13:57
Tralokinumab improves symptoms and quality of life in adolescents with moderate-to-severe AD 22 November, 2022 17:09
Baricitinib possible therapeutic option for children with AD Presented ByDr Antonio Torrelo Fernández, Hospital Infantil Universitario Niño Jesús, Spain TrialPhase 3, BREEZE-AD-PEDS ConferenceEADV 2022 5 November, 2022 09:15
Amlitelimab therapy leads to sustained decrease of IL-22 in AD patients Presented ByDr Stephan Weidinger, University Hospital Schleswig-Holstein, Germany ConferenceEADV 2022 5 November, 2022 09:10
IL-13 inhibition with lebrikizumab shows high maintenance rates in AD Presented ByProf. Andrew Blauvelt, Oregon Medical Research Center, OR, USA TrialPhase 3, ADvocate ConferenceEADV 2022 5 November, 2022 09:05
Does 8 weeks of emollients use prevent AD in high-risk infants? Presented ByProf. Alan Irvine, Trinity College Dublin, Ireland TrialSTOP AD ConferenceEADV 2022 5 November, 2022 09:02
Therapies for atopic dermatitis: still moving forward Presented ByProf. Christian Vestergaard, Aarhus University Hospital, Denmark ConferenceSPIN 2022 26 August, 2022 10:58
Children with AD: high risk of bacterial infections in carriers of a filaggrin gene variant Presented ByProf. Alina Suru , Carol Davila University of Medicine and Pharmacy, Romania ConferenceSPIN 2022 26 August, 2022 10:53
No adverse pregnancy outcomes in patients exposed to baricitinib ConferenceSPIN 2022 26 August, 2022 10:47
AD treatment during the pandemic: dupilumab does not raise COVID-19 infection risk Presented ByDr Brian Rankin, University of Calgary, Canada TrialCohort study ConferenceAAD 2022 18 May, 2022 12:27
Upadacitinib: Fast and more pronounced skin improvement in AD patients Presented ByProf. Jonathan Silverberg, George Washington University School of Medicine, USA TrialPhase 3, Heads Up ConferenceAAD 2022 17 May, 2022 12:35
JAK inhibitors in AD: Setting the efficacy bar even higher Presented ByProf. Eric Simpson, Oregon Health & Science University, USA TrialMeasure Up 1; JADE Mono-1; JADE Compare; Heads Up ConferenceAAD 2022 17 May, 2022 12:21
Novel IL-4/IL-13 blocker shows high efficacy with only modest conjunctivitis signal Presented ByProf. Andrew Blauvelt, Oregon Medical Research Center, USA ConferenceAAD 2022 17 May, 2022 12:15
JAK inhibitors: A risk assessment Presented ByProf. Brett King, Yale School of Medicine, USA ConferenceAAD 2022 17 May, 2022 10:59
Monitoring is key during JAK inhibitor therapy Presented ByProf. Jonathan Silverberg ConferenceAAD 2022 17 May, 2022 10:47
AAD 2022 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceAAD 2022 14 April, 2022 11:02
Dupilumab for atopic dermatitis linked with milder COVID-19 symptoms JournalThe Journal of Allergy and Clinical Immunology: In Practice 25 November, 2021 16:58
Targeting OX40 in the treatment of atopic dermatitis meets expectations Presented ByProf. Stephan Weidinger, University Hospital Schleswig-Holstein, Germany TrialPhase 2 ConferenceEADV 2021 18 November, 2021 13:35
Superior EASI scores after switch from dupilumab to upadacitinib Presented ByProf. Andrew Blauvelt, Oregon Medical Research Center, USA TrialHeads Up ConferenceEADV 2021 18 November, 2021 13:34
Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083 Presented ByProf. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA TrialPhase 2 ConferenceEADV 2021 18 November, 2021 13:28
Abrocitinib demonstrates fast itch control and skin clearance in atopic dermatitis Presented ByProf. Kristian Reich, University Medical Center Hamburg-Eppendorf, Germany TrialPhase 3, JADE DARE ConferenceEADV 2021 18 November, 2021 13:26
AD patients with stable response fare well with a monthly dose of tralokinumab Presented ByProf. Stephan Weidinger, University of Kiel, Germany TrialECZTRA1 and 2 ConferenceEADV 2021 18 November, 2021 13:25
Upadacitinib beats dupilumab in different body regions Presented ByProf. Jacob Thyssen, Bispebjerg Hospital, Denmark TrialPhase 3, Heads Up ConferenceEADV 2021 18 November, 2021 13:23
Efficacious 2-year AD control with IL-13 inhibitor tralokinumab Presented ByProf. Andrew Blauvelt, Oregon Medical Research Center, USA TrialECZTEND ConferenceEADV 2021 18 November, 2021 13:22
Ruxolitinib cream: a safe treatment for elderly AD patients Presented ByProf. Jacek Szepietowksi, Wroclaw Medical University, Poland TrialPhase 3, TRuE-AD1; TRuE-AD2 ConferenceEADV 2021 18 November, 2021 13:21
Novel and upcoming targeted AD treatment Presented ByProf. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA TrialECZTRA 3; Measure Up; ADVISE ConferenceEADV 2021 18 November, 2021 13:20
Opioid receptor agonist difelikefalin disappoints in AD Presented ByProf. Brian Kim, Washington University School of Medicine, USA TrialPhase 2, KARE ConferenceEADV 2021 17 November, 2021 14:28
Targeting oncostatin M curbs chronic itch in mice JournalScience Translational Medicine 16 November, 2021 22:22
EADV 2021 Highlights Podcast Presented ByDr Rachel Giles, Medicom TrialPSOARING 3, JADE-DARE, HEADS UP ConferenceEADV 2021 19 October, 2021 00:08
Potential first-in-class drug shows disease-modifying impact in atopic dermatitis ConferenceEuropean Academy of Dermatology and Venereology 30th Virtual Congress 8 October, 2021 22:39
Do oral corticosteroids drive fracture risk in atopic eczema? JournalJournal of Allergy and Clinical Immunology: In Practice 1 October, 2021 21:52
Severe atopic dermatitis tied to depressive symptoms, internalizing behaviors in children JournalJAMA Dermatology 7 September, 2021 20:50
Oral abrocitinib plus topical therapy safe, effective for teens with moderate-to-severe atopic dermatitis JournalJAMA Dermatology 24 August, 2021 23:13
Upadacitinib bests dupilumab for adults with moderate-severe atopic dermatitis JournalJAMA Dermatology 10 August, 2021 22:22
Autologous bacteriotherapy shows promise against atopic dermatitis JournalJAMA Dermatology 24 June, 2021 17:39
Comorbidity does not influence crisaborole efficacy in atopic dermatitis TrialPhase 3, CrisADe CORE 1 and 2 ConferenceAAD VMX 2021 7 June, 2021 13:30
Comorbidity is common in adult and paediatric atopic dermatitis patients Presented ByProf. Jonathan Silverberg, George Washington University, WA, USA ConferenceAAD VMX 2021 7 June, 2021 13:30
Significant improvements in the system armamentarium for AD treatment Presented ByProf. Eric Simpson, Oregon Health & Science University, USA ConferenceAAD VMX 2021 7 June, 2021 13:20
No increased risk of infection with long-term dupilumab for atopic dermatitis TrialLIBERTY AD OLE ConferenceAAD VMX 2021 7 June, 2021 13:15
Topical pan-JAK inhibitor cream safe and efficacious in atopic dermatitis Presented ByProf. Jonathan Silverberg, George Washington University, WA, USA ConferenceAAD VMX 2021 7 June, 2021 13:10
Atopic dermatitis in children has a severe impact on their families ConferenceAAD VMX 2021 7 June, 2021 13:05
Meaningful amelioration of quality of life in paediatric AD patients on dupilumab TrialPhase 3, LIBERTY AD PEDS ConferenceAAD VMX 2021 7 June, 2021 13:00
Etrasimod – a new mode of action for treatment of atopic dermatitis Presented ByProf. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA ConferenceAAD VMX 2021 7 June, 2021 10:45
Baricitinib shows long-term effectiveness against moderate to severe atopic dermatitis JournalJAMA Dermatology 4 June, 2021 16:35
Internet-delivered CBT improves atopic dermatitis symptoms JournalJAMA Dermatology 27 May, 2021 21:53
Oral JAK1 inhibitor shows promise for treating moderate to severe atopic dermatitis JournalThe Lancet 21 May, 2021 22:53
Wildfire air pollution linked to jump in atopic dermatitis and itch dermatology visits JournalJAMA Dermatology 21 April, 2021 23:37
Atopic dermatitis linked to learning disability, educational achievement JournalJAMA Dermatology 20 April, 2021 00:07
Topical calcineurin inhibitors pose very little cancer risk JournalJAMA Dermatology 8 April, 2021 17:36
Pfizer’s atopic dermatitis drug bests dupilumab, but only at higher dose JournalThe New England Journal of Medicine 24 March, 2021 23:40
Pediatric atopic dermatitis tied to school, work absenteeism JournalJournal of the American Academy of Dermatology 10 March, 2021 23:09
Severe atopic eczema tied to higher risk of premature death JournalJournal of Allergy and Clinical Immunology 28 January, 2021 16:09
Meaningful sleep improvement with IL-13 inhibition Presented ByProf. Jonathan Silverberg, George Washington University, USA TrialPhase 3, ECZTRA ConferenceEADV 2020 17 December, 2020 14:33
Baricitinib in AD: Efficacy paired with consistent long-term results Presented ByProf. Jonathan Silverberg , George Washington University, USA TrialPhase 3, BREEZE-AD3 ConferenceEADV 2020 17 December, 2020 14:31
Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD Presented ByProf. Megan Landis, University of Louisville School of Medicine, USA TrialPhase 2 ConferenceEADV 2020 17 December, 2020 14:22
Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD Presented ByProf. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA TrialPhase 3, Measure Up ConferenceEADV 2020 17 December, 2020 13:24
Effects IL-13 blocker improves with longer treatment duration Presented ByProf. Eric Simpson, Oregon Health & Science University, USA TrialPhase 3, ECZTRA ConferenceEADV 2020 17 December, 2020 12:37
Baricitinib plus corticosteroids effectively treats atopic dermatitis JournalJAMA Dermatology 9 October, 2020 23:27
Baricitinib beneficial in head and neck AD Presented ByDr Eric Simpson, Oregon Health and Science University, USA TrialPhase 3, BREEZE-AD1 and BREEZE-AD2 ConferenceAAD 2020 19 August, 2020 07:23
Good response and pruritus reduction in AD with novel selective JAK1 inhibitor Presented ByDr Melinda Gooderham TrialJADE MONO-2 ConferenceAAD 2020 6 August, 2020 07:08
IL-13 blocker tralokinumab effective in AD Presented ByProf. Eric Simpson TrialECZTRA ConferenceAAD 2020 6 August, 2020 07:06
Tape stripping – a painless way to distinguish AD and psoriasis? Presented ByDr Robert Bissonnette, Innovaderm Research, Canada ConferenceAAD 2020 6 August, 2020 07:05
IL-4/IL-13 blocker dupilumab effective in children with severe AD Presented ByProf. Amy S. Paller, Northwestern University Feinberg School of Medicine, USA TrialPhase 3, LIBERTY AD PEDS ConferenceAAD 2020 6 August, 2020 07:04
Small molecules: interesting novel treatment options in AD Presented ByProf. Tilo Biedermann, Helmholtz Center Munich, German ConferenceEADV 2019 9 December, 2019 20:27
IL-1⍺ blockade: a new treatment option in AD Presented ByProf. Alice Gottlieb, Icahn School of Medicine at Mount Sinai, USA ConferenceEADV 2019 9 December, 2019 19:51
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents Presented ByProf. Eric Simpson, Oregon Health & Science University, USA TrialPhase 3, LIBERTY AD ADOL ConferenceEADV 2019 9 December, 2019 18:58
JAK inhibition plus TCS lead to high clearance rates in AD Presented ByProf. Kristian Reich, Georg-August-University Göttingen, Germany TrialPhase 3, BREEZE-AD7 9 December, 2019 16:53
How to manage conjunctivitis in AD patients treated with a biologic Presented ByProf. Tilo Biedermann, Helmholtz Center Munich, Germany ConferenceEADV 2019 9 December, 2019 16:01
Biologics: increasingly used in paediatric dermatology Presented ByProf. Marieke Seyger, Radboud University Nijmegen, the Netherlands ConferenceEADV 2019 9 December, 2019 15:16
No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD Presented ByProf. Regina Fölster-Holst, University Medical Center Schleswig-Holstein, Germany TrialAPPLES ConferenceEADV 2019 9 December, 2019 15:04
Green light for a second JAK inhibitor in AD Presented ByProf. Eric Simpson, Oregon Health & Science University, USA TrialPhase 3, JADE MONO-1 ConferenceEADV 2019 9 December, 2019 14:06
Comorbidities more common in chronic urticaria, psoriasis, and AD Presented ByDr Karsten Weller, Charité University Hospital, Germany ConferenceEADV 2019 9 October, 2019 20:40
Reduced sleep quality in dermatoses influenced by itch and pain Presented ByDr Karolina Kaaz, Wroclaw Medical University, Poland ConferenceEADV 2019 9 October, 2019 19:58
Anxiety and depression are common in families of AD infants Presented ByDr Vesna Grivcheva-Panovska, University Clinic in Skopje (Macedonia) ConferenceEADV 2019 9 October, 2019 18:59
Cutaneous adverse events due to EGFR inhibitors Presented ByDr Pietro Sollena, University of the Sacred Heart in Rome, Italy ConferenceWCD 2019 26 August, 2019 20:44
Insights into pathogenesis of AD define novel therapeutic targets Presented ByProf. Graham Ogg & Prof. Emma Guttman-Yassky ConferenceWCD 2019 26 August, 2019 20:29
Long awaited oral therapy for moderate-to-severe AD Presented ByProf. Thomas Bieber, University Medical Center Bonn, Germany ConferenceWCD 2019 26 August, 2019 19:14
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis Presented ByDr Nehal Mehta; Prof. Emma Guttman-Yassky TrialNHANES ConferenceSPIN 2019 21 June, 2019 14:38
Atopic dermatitis and psoriasis: on a spectrum? Presented ByProf. Emma Guttman-Yassky, Mount Sinai Medical School, USA ConferenceSPIN 2019 21 June, 2019 13:39
Bermekimab – a future treatment for atopic dermatitis? Presented ByProf. Eric Simpson, Oregon Health & Science University, USA ConferenceAAD 2019 19 April, 2019 22:17
New and emerging atopic dermatitis therapies Presented ByProf. David Cohen, New York University School of Medicine, USA ConferenceAAD 2019 19 April, 2019 20:43
Tralokinumab improves eczema and reduces staphylococcus aureus colonisation in AD ConferenceAAD 2019 19 April, 2019 18:14
Can JAK inhibitors close the current therapeutic gap in AD? Presented ByProf. Eric Simpson, Oregon Health & Science University, USA ConferenceAAD 2019 19 April, 2019 14:12
Living in the golden age of psoriasis and atopic dermatitis therapies ExpertDr Erik Joseph Stratman, Marshfield Clinic, Wisconsin, USA ConferenceAAD 2018 21 December, 2018 16:46